Seth Lederman, Tonix Pharmaceuticals CEO

Tonix will test its mon­key­pox vac­cine in Kenya next year, and no eyes on ac­cel­er­at­ed path at FDA

As mon­key­pox spreads across dozens of coun­tries, one of the few biotechs pub­licly work­ing on a new vac­cine for the virus is gear­ing up to en­ter the clin­ic in the first half of next year.

The study of Tonix Phar­ma­ceu­ti­cals’ live virus vac­cine will oc­cur at Kenya Med­ical Re­search In­sti­tute, or KEM­RI, in the East African coun­try, the part­ners said Thurs­day. While Kenya has no re­port­ed cas­es of the virus that leads to painful le­sions, the coun­try is close to the De­mo­c­ra­t­ic Re­pub­lic of the Con­go, which had 163 cas­es as of Ju­ly 27, ac­cord­ing to a CDC track­er.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.